AI Driven Drug Discovery/Absci leverages Ai and synthetic biology to revoltionize drug development, reducing costs and timelines, giving them a significant edge in the biotech sector Scalable Platform / Their technology platfrom is highly scalable, improving efficiency with each new project. This makes Absci increasingly competitive as the platform matures.Read more
Absci is trying to use AI to design new antibody medicines, with its lead program aimed at both hair loss and endometriosis—two huge markets where patients often pay out of pocket and options are limited. The upside hinges on upcoming human trial results and whether big drug companies keep signing partnership deals, but delays or weak data could quickly change the story.Read more
Absci is betting on an AI-driven drug platform and a single lead medicine that aims to treat both hair loss and endometriosis with a more convenient, longer-lasting approach. The upside hinges on upcoming study results and new partnership deals, but any weak safety or effectiveness signals could quickly derail the story.Read more
Catalysts About Absci Absci uses an AI driven platform to design and develop biologic drug candidates, including its own antibody pipeline and partnered discovery programs. What are the underlying business or industry changes driving this perspective?Read more
No trending discussion available.
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
